Search Results

You are looking at 101 - 110 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

Athanassios Argiris

Surg 1987 ; 10 : 19 – 30 . 3 Taylor SGT . Why has so much chemotherapy done so little in head and neck cancer? J Clin Oncol 1987 ; 5 : 1 – 3 . 4 Rosenthal DI Pistenmaa DA Glatstein E . A review of neoadjuvant chemotherapy

Full access

Gary L. Gallia, Steven Brem and Henry Brem

Schoenfeld D . Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

Full access

Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi and Kathryn J. Ruddy

Chemotherapy-induced nausea and vomiting (CINV) is common during cancer treatment due to a complex multifactorial process involving several different pathways and transmitters. Highly emetogenic chemotherapy (HEC) regimens are associated with >90

Full access

Crystal Weaver, Mark Varvares, Elaine Ottenlips, Kara Christopher and Andrew Dwiggins

anxiety levels of oncology patients during chemotherapy treatments. Purpose: To determine if listening to live music performed by community musicians decreases oncology patient anxiety levels during chemotherapy treatments in an outpatient infusion

Full access

Adrienne G. Waks and Ann H. Partridge

heterogeneity in outcomes between patients, and only limited research has identified important patient-specific determinants beyond age. In one retrospective study of premenopausal patients with breast cancer, the odds ratio of developing chemotherapy

Full access

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein and Cheryl Pegus

Several oral chemotherapies and biologic therapies have been introduced in the past decade for use alone and combined with intravenous chemotherapy. The role of oral chemotherapy agents in cancer management will likely increase. 1 Oral

Full access

Pelin Cinar and Andrew H. Ko

treatment options for patients with locally advanced unresectable PDAC Explain the roles of systemic therapy and chemoradiation for locally advanced PDAC including optimal sequencing, recent improvements in chemotherapy, and whether radiotherapy improves

Full access

Megan Gershon, Justine Pena, Chamnjot Bains, Sarah Salas, Tresa McGranahan and Seema Nagpal

Background: The development of oral chemotherapies (OC) have transformed cancer care for millions of patients. Most patients with brain tumors have temozolomide (TMZ) delivered to their home. While this has improved the patient experience, it

Full access

Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou and Rudolph M. Navari

Background: Avoiding acute care services can improve cancer care and reduce cost. The US Centers for Medicare and Medicaid Services’ (CMS) new oncology outcome measure (OP-35) defines 30-day post-chemotherapy inpatient (IP) and/or emergency

Full access

Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas and Lynne I. Wagner

Overview Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. 1 – 10 The symptom